US Markets

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Credit: REUTERS/Dado Ruvic

Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.

Adds details on trial, other vaccine candidate

Aug 25 (Reuters) - Translate Bio Inc TBIO.O said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA SASY.PA induced immune response in non-human studies, with trials in humans expected to start in November.

In a regulatory filing, the company cited Sanofi's presentation slides showing that three doses of the vaccine candidate induced neutralizing antibodies and T-cell responses in animal studies.

Translate, which signed a potential $2 billion vaccine development deal with Sanofi last month, said their vaccine candidate is set to be evaluated in an early- to mid-stage human trial.

Other drugmakers racing to develop a safe and effective vaccine for COVID-19 are further ahead in their testing, with Moderna MRNA.O, Johnson and Johnson JNJ.N and Pfizer PFE.N starting their late-stage studies.

Translate's vaccine, like Moderna's, uses mRNA technology which delivers proteins that produce immune response against the disease directly to target cells.

Sanofi is developing another COVID-19 vaccine candidate with British drugmaker GlaxoSmithKline Plc GSK.L.

In July, the U.S. government said it is providing $2.1 billion to Sanofi and GSK for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing.

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology.

UPDATE 1-U.S. to pay $2.1 bln to Sanofi, GSK, in COVID-19 vaccine deal

FACTBOX- The race for a coronavirus vaccine

(Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Maju Samuel)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRNA JNJ PFE GSK

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More